for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

GlaxoSmithKline plc (ADR)

GSK

Latest Trade

39.51USD

Change

0.28(+0.71%)

Volume

3,755,818

Today's Range

39.38

 - 

39.59

52 Week Range

33.26

 - 

42.40

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
39.23
Open
39.50
Volume
3,755,818
3M AVG Volume
89.23
Today's High
39.59
Today's Low
39.38
52 Week High
42.40
52 Week Low
33.26
Shares Out (MIL)
5,029.98
Market Cap (MIL)
97,930.73
Forward P/E
14.80
Dividend (Yield %)
5.50

Next Event

Q2 2021 GlaxoSmithKline PLC Earnings Release

Latest Developments

More

GSK Appoints Brian Mcnamara As CEO Designate Of New Consumer Healthcare Co

Sanofi: rolling reviews of COVID-19 recombinant vaccine to start soon in UK, Canada and Singapore

EU Drugs Regulator Starts Rolling Review Of Sanofi/GSK COVID-19 Vaccine

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About GlaxoSmithKline plc (ADR)

GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.

Industry

Major Drugs

Contact Info

G S K House, 980 Great West Road

TW8 9GS

United Kingdom

+44.20.80475000

https://www.gsk.com/

Executive Leadership

Jonathan Richard Symonds

Independent Non-Executive Chairman of the Board

Emma N. Walmsley

Chief Executive Officer, Executive Director

Iain James Mackay

Chief Financial Officer, Executive Director

Roger G. Connor

President - Global Vaccines

Brian McNamara

Chief Executive Officer - GSK Consumer Healthcare

Key Stats

2.20 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

41.1K

2019

43.1K

2020

43.7K

2021(E)

44.6K
EPS (USD)

2018

3.104

2019

3.161

2020

2.973

2021(E)

2.670
Price To Earnings (TTM)
13.74
Price To Sales (TTM)
2.20
Price To Book (MRQ)
4.86
Price To Cash Flow (TTM)
11.15
Total Debt To Equity (MRQ)
176.38
LT Debt To Equity (MRQ)
155.04
Return on Investment (TTM)
11.51
Return on Equity (TTM)
7.35

Latest News

Latest News

BRIEF-GSK Appoints Brian Mcnamara As CEO Designate Of New Consumer Healthcare Co

* GLAXOSMITHKLINE PLC - CEO DESIGNATE OF NEW CONSUMER HEALTHCARE COMPANY

EU begins real-time review of Sanofi-GSK COVID-19 vaccine

Europe's drug regulator said on Tuesday it had started a real-time review of the COVID-19 vaccine developed by French drugmaker Sanofi and Britain's GlaxoSmithKline, the fifth shot currently under such a review.

BRIEF-GSK Says ViiV Healthcare Study Shows New Long-Acting HIV Regimen Cabenuva Can Be Used In US Healthcare Practices

* GSK-VIIV HEALTHCARE STUDY SHOWS NEW LONG-ACTING HIV REGIMEN CABENUVA CAN BE USED IN BROAD RANGE OF US HEALTHCARE PRACTICES, EVEN DURING COVID-19 Source text for Eikon: Further company coverage:

GSK anaemia drug shows promise as treatment in kidney disease patients

GSK said on Friday its anaemia drug for patients with kidney disease succeeded in late-stage trials, marking an important milestone for the British drugmaker as it bolsters its pipeline ahead of a split with its consumer healthcare venture.

BRIEF-GlaxoSmithKline Announces Daprodustat Phase 3 Headline Results

* GLAXOSMITHKLINE PLC - GSK ANNOUNCES DAPRODUSTAT PHASE 3 HEADLINE RESULTS

Drugmaker GSK plans $550 million expansion of England R&D facility

Britain's GlaxoSmithKline on Friday laid out plans to set up a new life sciences campus within its R&D site in Stevenage, England, raising up to 400 million pounds ($552.76 million) by selling some land at the facility.

BRIEF-GSK Unveils Plan For Europe's Life Science Campuses In Stevenage

* GSK - UNVEILS PLAN FOR ONE OF EUROPE'S LARGEST LIFE SCIENCE CAMPUSES IN STEVENAGE

Italy approves GSK-Vir antibody to treat COVID-19

Italy approved the temporary distribution of a coronavirus antibody treatment by Britain's GlaxoSmithKline and U.S. company Vir Biotechnology, the health ministry said in a statement on Tuesday.

Sanofi, GSK get Indian approval for late-stage trial of COVID-19 vaccine

Sanofi SA and GlaxoSmithKline Plc have received an approval from Indian authorities for a late-stage clinical trial of their protein-based COVID-19 vaccine candidate, the drugmakers said on Thursday.

GSK, Alector to develop Parkinson's, Alzheimer's drugs in $2.2 billion deal

GlaxoSmithKline Plc and U.S. firm Alector Inc will together develop antibody-based treatments for Parkinson's, Alzheimer's and other similar diseases in a deal worth up to $2.2 billion, the drugmakers said on Friday.

BRIEF-GSK Backs CEO Walmsley In Response To Elliott's Letter

* GSK - NOTES LETTER ISSUED BY ELLIOTT ADVISORS (UK) LIMITED ("ELLIOTT") ON 1 JULY

Investor Elliott wants GSK leadership settled before split

Activist investor Elliott said GlaxoSmithKline should review its leadership and consider a sale of its consumer healthcare business as it confirmed on Thursday that it had taken a significant stake in the British pharmaceuticals group.

BRIEF-Elliott Advisors (UK) Publishes Letter On GlaxoSmithKline

* BELIEVES GSK HAS SUBSTANTIAL VALUE CREATION OPPORTUNITY-45% UPSIDE IN ITS SHARE PRICE-AHEAD OF CONSUMER HEALTH SEPARATION AND GREATER BEYOND

Sanofi sells portfolio of regional consumer brands to Stada

French drugmaker Sanofi on Monday said it agreed to sell 16 mainly European consumer healthcare brands to private-equity owned Stada to streamline its product portfolio.

GlaxoSmithKline taps Goldman, Citi to advise on consumer unit spinoff - Bloomberg News

GlaxoSmithKline Plc has hired two banks to help advise it on listing its consumer unit next year and on defense against a potential activist campaign from Elliott Investment Management, Bloomberg News reported https://www.bloomberg.com/news/articles/2021-06-25/glaxosmithkline-said-to-tap-goldman-citi-for-spinoff...

FTSE 100 rises on dovish BoE; miners, pharma stocks lead gains

Britain's FTSE 100 rose on Thursday, led by mining and healthcare-related stocks as the Bank of England kept its crisis-era monetary policy unchanged, while cruise operator Carnival fell after a quarterly loss of over $2 billion.

FTSE 100 marks time ahead of BoE meeting

London's FTSE 100 marked time ahead of the Bank of England's rate decision on Thursday, while GlaxoSmithKline rose on plans to spin off its healthcare arm.

BRIEF-GSK Announces Plans For Separation of Consumer Healthcare Unit

* GLAXOSMITHKLINE PLC - GSK TO DELIVER STEP-CHANGE IN GROWTH & PERFORMANCE

BRIEF-GlaxoSmithKline Says VIIV/Halozyme Sign Exclusive Licensing Agreement

* GLAXOSMITHKLINE PLC - VIIV/HALOZYME SIGN EXCLUSIVE LICENSING AGREEMENT

Study confirms GSK-Vir antibody drug reduces hospitalization, death in COVID-19 patients

GlaxoSmithKline Plc and Vir Biotechnology said on Monday final results from a late-stage study of their monoclonal antibody confirmed it significantly reduced hospitalization and death among high-risk COVID-19 patients when given early in the disease.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up